Compare EVO & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | XERS |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | Germany | United States |
| Employees | 4553 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 934.1M | 1.0B |
| IPO Year | N/A | 2021 |
| Metric | EVO | XERS |
|---|---|---|
| Price | $3.00 | $6.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.00 | ★ $10.83 |
| AVG Volume (30 Days) | 85.0K | ★ 1.6M |
| Earning Date | 04-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $1.37 | $34.37 |
| Revenue Next Year | $10.05 | $22.86 |
| P/E Ratio | ★ N/A | $638.48 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $2.31 | $4.30 |
| 52 Week High | $4.48 | $10.08 |
| Indicator | EVO | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 53.04 | 49.57 |
| Support Level | $2.88 | $5.79 |
| Resistance Level | $3.36 | $6.41 |
| Average True Range (ATR) | 0.09 | 0.32 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 54.34 | 28.51 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.